alert icon Important Updates + Notice of Vendor Data Event

Coming to a Cleveland Clinic location?
Hillcrest Cancer Center check-in changes
Cole Eye entrance closing
Visitation, mask requirements and COVID-19 information

Notice of Intelligent Business Solutions data event
Learn more

Richard Rudick, MD

Richard Rudick, MD
  • No ratings
  • 0 Patient Satisfaction Ratings
  • 0 Patient Comments
Department Mellen Center
Primary Location Cleveland Clinic Main Campus
Type of Doctor Adults Only
Languages English
Surgeon No
Cleveland Clinic Main Campus
Primary Location

Cleveland Clinic Main Campus


Additional Locations

Specialties & Treatments

Treatment & Services

  • Consultation and Long-term Care
  • Consultation On Medical And Epidemiological Research Design And Analysis.
View all 2 Treatment & Services +

Specialty in Diseases & Conditions

  • Acute Disseminated Encephalomyelitis (ADEM)
  • Central Nervous System Complications of Autoimmune Disease
  • Devic's Disease (Neuromyelitis Optica)
  • Neuroimmunology
View all 4 Specialties +


Is Cleveland Clinic Part of Your Insurance?

Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.

View All Plans

About Richard Rudick, MD

Richard A. Rudick, MD, is currently Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, the Hazel Prior Hostetler Chair of Neurology, Director of the Mellen Center for Multiple Sclerosis Treatment and Research, and Vice Chairman of Research and Development in the Neurological Institute at Cleveland Clinic.

Dr. Rudick graduated from Case Western Reserve University School of Medicine in 1975. Following internship and residency in medicine at the University of Connecticut, Dr. Rudick trained in neurology at the University of Rochester. During a postdoctoral research fellowship in the Center for Brain Research at the University of Rochester, studies focused on neurologic consequences of immune complex disease in animal systems and immunologic abnormalities in multiple sclerosis (MS) patients. Dr. Rudick’s subsequent studies on cerebrospinal fluid in MS were supported by an NIH clinical investigator career development award.

Dr. Rudick became Director of the Mellen Center in 1987. He has played key roles in several MS clinical trials, including pivotal registration trials of IFNß-1a (Avonex) and natalizumab (Tysabri) for relapsing-remitting MS. He continues studies on immunologic changes in MS patients, has led development of new clinical and imaging measures for MS trials and maintains a consultative clinical practice at the Mellen Center. Dr. Rudick has maintained continuous competitive grant funding from the NIH and the National Multiple Sclerosis Society for over 25 years.

Dr. Rudick established the Office of Clinical Research at Cleveland Clinic in 2001, and was the founding Chairman of the Division of Clinical Research in 2003. In that role, Dr. Rudick established a new General Clinical Research Center at Cleveland Clinic, secured a large Roadmap Clinical Research Training Program award from NIH (the Roadmap K12 Program), led a multidisciplinary effort to secure accreditation of the Cleveland Clinic Human Subjects Protection Program, and provided oversight for expansion of patient-based clinical and translational research. Dr. Rudick played a pivotal role in securing a Clinical and Translational Sciences Award from the NIH, serving as the CTSA Co-Principal Investigator. The CWRU/Cleveland Clinic CTSA created an academic home for clinical and translational research and city-wide infrastructure to support patient-based research.


Robert Fox, MD, is a Staff Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic. He received his medical degree from Johns Hopkins University, neurology residency training at the University of Pennsylvania, multiple sclerosis fellowship training at Cleveland Clinic, and a master’s degree in Clinical Research from Case Western Reserve University.
He serves as an advisory committee member and principal site investigator for many clinical trials, including coordinating global principal investigator for a Phase III clinical trial of dimethyl fumarate in relapsing remitting multiple sclerosis (MS).
Dr. Fox’s current research interests focus on innovative MRI techniques to evaluate MS treatments and tissue recovery after injury, where he is principal investigator and co-investigator on grants funded by the NIH and National MS Society. He serves as a member of various advisory and review committees for the National MS Society. He is also Managing Director of the NARCOMS MS Patient Registry, a member of the General Advisory Council and Research Programs Committee for the Cleveland Clinic General Clinical Research Center, and a consultant to the pharmaceutical industry regarding the development of new treatments for MS.
Education & Professional Highlights

Education & Professional Highlights


Additional Training

  • Masters of Science in Clinical Research, Case Western Reserve University, 2003

Professional Highlights

  • Vice Chairman, Research and Development, Neurological Institute, 2007-Present
  • Director, Mellen Center for Multiple Sclerosis Treatment and Research, and Hazel Prior Hostetler Professor of Neurology, 1987-Present
  • Chairman, Division of Clinical Research, Cleveland Clinic, 2003-2007
  • Co-Principal Investigator, Case Western Reserve University/Cleveland Clinic CTSA, 2000-Present
  • Principal Investigator, Cleveland Multidisciplinary Clinical Research Training Program (Roadmap K12 Program), 2004-Present
    Advisory Committee on Fellowships, National Multiple Sclerosis Society (Chair, 2011-2012)
  • International Coordinating Investigator, Phase III clinical trial of BG00012
  • Editorial Board, Neurology and Multiple Sclerosis Journal
  • Managing Director, NARCOMS MS Patient Registry
  • Scientific Expert Working Group on CCSVI, Canadian Institutes of Health Research
  • MS Clinical Phenotype Subcommittee, International Advisory Committee on Clinical Trials in MS
  • Medical Monitor, Phase I Study of Mesenchymal Stem Cell Transplantation in MS
  • Ad hoc reviewer, NIH ZRG1 BDCN-N Member Conflict Special Emphasis Panel
  • Committee for Responsible Research Conduct, Cleveland Clinic
  • Neurosciences Sub-Chair, Research Programs Committee, Cleveland Clinic

Specialty Interests

Multiple Sclerosis, Neuroimmunology

Awards & Honors

  • Alpha Omega Alpha Honorary Medical Society, elected as a Junior Student, Case Western Reserve University School of Medicine, 1974
  • Outstanding Alumnus of the Year Award, Ohio University College of Arts and Sciences, 1994
  • Bruce Hubbard Stewart Award for Humanistic Medicine, Cleveland Clinic, 1995
  • Hazel Prior Hostetler Professor of Neurology, Cleveland Clinic, 1996
  • Alumnus of the Year Award, Department of Neurology, University of Rochester, 1998
  • Innovation Award for Brain Parenchymal Fraction Software, Enterprise Development, Inc., 2000
  • Arnold and Geri King Lifetime Achievement Award, National Multiple Sclerosis Society, 2002
  • Health Care Professional Hall of Fame Award, National Multiple Sclerosis Society, 2003
  • Continuously funded by the National Institutes of Health (NINDS, NCRR) and the National MS Society, 1981-Present
  • National Center for Research Resources (NIH) Council, 2006-Present
  • Council of Councils Member (NIH Director's Office), 2007-Present
    1991    James Olds Memorial Neuroscience Thesis Award
  • 1992    Alpha Omega Alpha Honor Society Grant
  • 1996    Sellards Travel Award to Johannesburg, South Africa
  • 1996    Medical and Chirurgical Society of Maryland Award for Excellence in Organized Medicine
  • 1996    Harold Lamport Biomedical Research Prize, Johns Hopkins University
  • 1999    Zeritzky Resident Clinical Research Award, University of Pennsylvania
  • 2000    Potiker Fellow, Mellen Center for Multiple Sclerosis Treatment and Research
  • 2001    National Multiple Sclerosis Society Dale McFarlin Travel Award
  • 2003-2012    Top Doctors, Cleveland Magazine
  • 2008    Outstanding Physician/PA Team, Cleveland Clinic
  • 2009    Fellow, American Academy of Neurology
  • 2011    Researcher Hall of Fame, National MS Society

Innovations & Patents

  • Dr. Rudick is a recognized pioneer in the treatment and research of multiple sclerosis (MS). As an internationally recognized thought leader in the MS field, he is invited to provide lectures and consultations regarding clinical research programs in MS worldwide.


  • American Academy of Neurology
  • American Neurological Association
  • American Association for the Advancement of Science (Fellow)
  • American Association of Physicians
  • Alpha Omega Alpha Honorary Medical Society
    American Academy of Neurology
  • American Society of Neuroimaging
  • American Medical Association
Research & Publications

Research & Publications

See publications for Richard Rudick, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/7/2014, Dr. Rudick has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Rudick receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Biogen Idec, Inc.

Donation of Financial Interest. Dr. Rudick has consulted for, received compensation for serving as a fiduciary from, or received royalties from the following companies but instructed them to donate all compensation to not-for-profit causes or to the Cleveland Clinic to support research and education:

  • Genzyme Corporation

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Back to Top